Suraksha Diagnostic IPO Details
The key details of Suraksha Diagnostic’s IPO are outlined below, covering all crucial aspects from price range to investment requirements and regulatory documents.
| IPO Size | ₹846.25 Cr |
| Price Range | ₹420 - ₹441 |
| Retail Quota | 35% |
| QIB Quota | 50% |
| NII Quota | 15% |
| Employee Discount | -- |
| Listing at | NSE and BSE |
| Minimum Quantity | 34 |
| Investment (cut-off price) | ₹14,994 |
| Pre IPO Promotor Holding | 61.07% |
| Post IPO Promotor Holding | Update soon |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Suraksha Diagnostic IPO Timelines
The IPO process for Suraksha Diagnostic includes key dates for participants to know. The timeline allows for strategic planning and participation, helping investors stay informed and engaged throughout the entire process.
29/11/2024
Start Date03/12/2024
End Date05/12/2024
Refund Initiation05/12/2024
Credit of Shares to Demat Ac06/12/2024
Listing DateSuraksha Diagnostic IPO Lot Size
The Suraksha Diagnostic IPO has a fixed lot size of 34 shares, at an upper price band of ₹441 per share, requiring ₹14,994 per lot for retail investors. Retail investors can apply for a maximum of 442 shares worth ₹194,922. For Small HNI (S-HNI), the minimum application starts at 476 shares (₹209,916) up to 2,244 shares (₹989,604), while Big HNI (B-HNI) requires a minimum of 2,278 shares amounting to ₹1,004,598.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 34 | ₹14,994 |
| Retail Maximum | 13 | 442 | ₹194,922 |
| S-HNI Minimum | 14 | 476 | ₹209,916 |
| S-HNI Maximum | 66 | 2244 | ₹989,604 |
| B-HNI Minimum | 67 | 2278 | ₹1,004,598 |
Suraksha Diagnostic IPO Subscription Status
The subscription status for Suraksha Diagnostic IPO shows market demand across different investor categories, providing valuable insights into the offering’s performance. You can track real-time subscription data below.
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| 1.74x | 1.40x | 0.94x | -- | 1.27x |
IPO Performance on Listing Day
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹438 | ₹417.25 | ₹449 | ₹414.25 |
Suraksha Diagnostic IPO Company Financials
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2022 | ₹223.19 | ₹197.76 | ₹20.82 |
| FY 2023 | ₹190.13 | ₹186.94 | ₹6.07 |
| FY 2024 | ₹218.71 | ₹190.03 | ₹23.13 |
About Company
Suraksha Diagnostic Limited, established on March 15, 2005, is a prominent diagnostic service provider in East and Northeast India, offering integrated pathology, radiology, and medical consultation services. The company operates through a robust network comprising a central reference laboratory, 8 satellite labs, and 194 customer contact points, including 48 diagnostic centers and 146 sample collection centers. Accredited by the College of American Pathologists and NABL, Suraksha provides over 2,300 specialized tests across various medical disciplines, catering to diverse healthcare needs with state-of-the-art technology and operational excellence.
In addition to diagnostic services, Suraksha enhances patient care through 43 diagnostic centers housing 120 polyclinics with more than 750 in-house doctors offering consultations. Leveraging advanced systems like Laboratory Information Management System (LIMS), Radiology Information System (RIS), and artificial intelligence for diagnostics, the company ensures efficient operations and faster results. Its offerings also include vaccination services, customized testing packages for early disease detection, and digital pathology for blood testing. With a focus on innovation and patient convenience, Suraksha continues to lead in delivering comprehensive healthcare solutions.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 2005 | Healthcare | Somnath Chatterjee |
Know Before Investing
Suraksha Diagnostic IPO Strengths
- Strong foothold in Eastern India’s diagnostic market with significant growth opportunities in a fragmented industry.
- Offers a complete range of services, including pathology, radiology, and medical consultations.
- Advanced clinical infrastructure paired with skilled professionals ensures reliable and efficient services.
- Well-established brand with a focus on quality, driving growth in the individual consumer segment.
Suraksha Diagnostic IPO Risks
- The company’s strong dependence on West Bengal exposes it to potential risks, as any decline in business from this region could significantly affect overall performance.
- Staying updated with new tests and technologies is crucial to maintaining a competitive edge.
- Dependence on third-party vendors for equipment could pose operational risks if supply chains are disrupted.
- Franchise-run collection centers may impact quality and reputation if standards are not maintained.
- Intense competition in the diagnostics industry could pressure pricing and profitability.
- High debt levels and financial obligations may limit flexibility and strain financial health.
Swot Analysis for Suraksha Diagnostic IPO
Strengths
Integrated diagnostic services, Extensive operational network, High-quality standards
Weaknesses
Geographical concentration, Limited technological advancements in diagnostic equipment
Opportunities
Growing healthcare demand, Potential for service expansion
Threats
Intense competition, Regulatory changes affecting healthcare services
Company Details
Suraksha Diagnostic Limited
Plot No. DG-12/1
Action Area 1D, Premises No. 02-0327
New Town, Rajarhat Kolkata 700 156
Phone: 91 33 66059750
Email: investors@surakshanet.com
Website: https://www.surakshanet.com/
IPO Registar Details
Kfin Technologies Limited
Phone: 04067162222, 04079611000
Email: sdl.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/
FAQs
The key objectives of Suraksha Diagnostic IPO are:
- All proceeds from the Offer for Sale will be allocated to the Selling Shareholders.
ICICI Securities Limited, Nuvama Wealth Management Limited, SBI Capital Markets Limited are the book-running lead managers for the Suraksha Diagnostic IPO.